Literature DB >> 6284361

Phase II trial of doxorubicin therapy for advanced islet cell carcinoma.

C G Moertel, P T Lavin, R G Hahn.   

Abstract

Twenty evaluable patients with advanced islet cell carcinoma were treated with doxorubicin at a dosage of 60 mg/m2 every 3-4 weeks. Toxicity was clinically tolerable and characteristic of doxorubicin therapy. Although all patients had previously been treated with other chemotherapy regiments, four (20%) had objective therapeutic responses persisting for 2-301/2 months. Doxorubicin has definite therapeutic activity in islet cell carcinoma and is currently being evaluated in combination chemotherapy regimens.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6284361

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  7 in total

Review 1.  Clinical pathways for pancreatic neuroendocrine tumors.

Authors:  Angela Alistar; Max Sung; Michelle Kim; Randall F Holcombe
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 2.  Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options.

Authors:  H N Nguyen; B Backes; F Lammert; J Wildberger; R Winograd; N Busch; H Rieband; S Matern
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

Review 3.  Current diagnosis and management of Zollinger-Ellison syndrome.

Authors:  D K Andersen
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

4.  Zollinger-Ellison Syndrome.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

5.  A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

Authors:  I Duran; J Kortmansky; D Singh; H Hirte; W Kocha; G Goss; L Le; A Oza; T Nicklee; J Ho; D Birle; G R Pond; D Arboine; J Dancey; S Aviel-Ronen; M-S Tsao; D Hedley; L L Siu
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

6.  Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up.

Authors:  Suayib Yalcin; Fahri Bayram; Sibel Erdamar; Ozlem Kucuk; Nevin Oruc; Ahmet Coker
Journal:  Arch Med Sci       Date:  2017-01-25       Impact factor: 3.318

7.  Mitoxantrone in metastatic apudomas: a phase II study of the EORTC Gastro-Intestinal Cancer Cooperative Group.

Authors:  J P Neijt; A J Lacave; T A Splinter; B G Taal; C H Veenhof; T Sahmoud; C J Lips
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.